1. Home
  2. BGX vs BDTX Comparison

BGX vs BDTX Comparison

Compare BGX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$10.64

Market Cap

139.7M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.14

Market Cap

116.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
BDTX
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
116.8M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
BGX
BDTX
Price
$10.64
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$10.40
AVG Volume (30 Days)
139.4K
564.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.45
EPS
N/A
0.65
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.28
Revenue Growth
N/A
N/A
52 Week Low
$10.38
$1.20
52 Week High
$12.65
$4.94

Technical Indicators

Market Signals
Indicator
BGX
BDTX
Relative Strength Index (RSI) 27.57 40.78
Support Level N/A $1.93
Resistance Level $11.89 $2.67
Average True Range (ATR) 0.14 0.14
MACD 0.00 -0.01
Stochastic Oscillator 39.23 26.76

Price Performance

Historical Comparison
BGX
BDTX

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Share on Social Networks: